Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
ACADIA Pharmaceuticals Inc. - Common Stock
(NQ:
ACAD
)
25.32
+1.60 (+6.75%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,370,514
Open
26.38
Bid (Size)
25.12 (100)
Ask (Size)
25.50 (100)
Prev. Close
23.72
Today's Range
25.07 - 27.31
52wk Range
19.69 - 28.35
Shares Outstanding
162,625,379
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Acadia Pharmaceuticals Stock Is Soaring Today
↗
June 26, 2026
An approval of one of its drugs for a major market is now looking likely.
Via
The Motley Fool
Traders are paying attention to the gapping stocks in Friday's session.
↗
June 26, 2026
Via
Chartmill
Performance
YTD
-3.7%
-3.7%
1 Month
+19.5%
+19.5%
3 Month
+22.0%
+22.0%
6 Month
-8.3%
-8.3%
1 Year
+14.0%
+14.0%
More News
Read More
Apogee Enterprises Posts Strong Q1 Earnings, Joins ACADIA Pharmaceuticals, Crocs And Other Big Stocks Moving Higher On Friday
↗
June 26, 2026
Via
Benzinga
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
June 26, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals (NASDAQ:ACAD) Q1 2026 Earnings Miss Sends Stock Lower
↗
May 06, 2026
Via
Chartmill
Topics
Earnings
ACADIA Pharmaceuticals Spotlights Alzheimer’s Psychosis Pipeline, NUPLAZID and DAYBUE Growth
↗
May 19, 2026
Via
MarketBeat
ACADIA Pharmaceuticals Targets $1B Brand Opportunity as Key Neuropsychiatry Data Looms
↗
May 12, 2026
Via
MarketBeat
Acadia (ACAD) Q1 2026 Earnings Transcript
↗
May 06, 2026
Via
The Motley Fool
Acadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
May 06, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
April 30, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
April 28, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
April 17, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 6, 2026
April 15, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Neurocrine Biosciences to Acquire Celeno Therapeutics in Rare Disease Deal
April 07, 2026
Via
MarketMinute
Soleno Therapeutics: A Masterclass in Rare Disease Redemption and the $2.9B Exit
April 07, 2026
Via
Finterra
Topics
Economy
Intellectual Property
Acadia Pharmaceuticals Announces DAYBUE® STIX (trofinetide) is Now Broadly Available in the United States for the Treatment of Rett Syndrome
April 07, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Neurocrine Biosciences to Acquire Soleno Therapeutics in $2.9 Billion Deal as VYKAT™ XR Sales Soar
April 06, 2026
Via
MarketMinute
Topics
Intellectual Property
Acadia Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum
March 12, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Acadia Pharmaceuticals Appoints Jonathan M. Poole to its Board of Directors
March 03, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Investment Manager Bets Big on PTCT Stock, Adds 41,000 Shares, According to Recent SEC Filing
↗
March 03, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Acadia Pharmaceuticals Announces Plan to Request Re-Examination Following Negative CHMP Opinion for Trofinetide for the Treatment of Rett Syndrome
March 02, 2026
From
Acadia Pharmaceuticals Inc.
Via
Business Wire
Investment Firm Adds Nearly $4 Milllion Worth of DYN Shares, According to Recent SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Investment Advisor Bets Big on CMPX Stock, Adds 2.5 Million Shares, According to Latest SEC Filing
↗
March 02, 2026
Via
The Motley Fool
Topics
Regulatory Compliance
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts
↗
February 27, 2026
Via
Stocktwits
ACADIA (ACAD) Q4 2025 Earnings Call Transcript
↗
February 25, 2026
Via
The Motley Fool
Topics
Earnings
Frequently Asked Questions
Is ACADIA Pharmaceuticals Inc. - Common Stock publicly traded?
Yes, ACADIA Pharmaceuticals Inc. - Common Stock is publicly traded.
What exchange does ACADIA Pharmaceuticals Inc. - Common Stock trade on?
ACADIA Pharmaceuticals Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock?
The ticker symbol for ACADIA Pharmaceuticals Inc. - Common Stock is ACAD on the Nasdaq Stock Market
What is the current price of ACADIA Pharmaceuticals Inc. - Common Stock?
The current price of ACADIA Pharmaceuticals Inc. - Common Stock is 25.32
When was ACADIA Pharmaceuticals Inc. - Common Stock last traded?
The last trade of ACADIA Pharmaceuticals Inc. - Common Stock was at 06/26/26 04:00 PM ET
What is the market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock?
The market capitalization of ACADIA Pharmaceuticals Inc. - Common Stock is 4.12B
How many shares of ACADIA Pharmaceuticals Inc. - Common Stock are outstanding?
ACADIA Pharmaceuticals Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.